

**TITLE:** Reductions in stillbirths and preterm birth in COVID-19 vaccinated women: a multi-center cohort study of vaccination uptake and perinatal outcomes

**AUTHORS:** Lisa HUI<sup>1,2,3,4</sup>, Melvin Barrientos MARZAN<sup>1,2,5</sup>, Daniel L. ROLNIK<sup>6,7,12</sup>, Stephanie POTENZA<sup>3</sup>, Natasha PRITCHARD<sup>1,3</sup>, Joanne M. SAID<sup>1,8</sup>, Kirsten R PALMER<sup>6,7</sup>, Clare L. WHITEHEAD<sup>1,9</sup>, Penelope M. SHEEHAN<sup>7,10</sup>, Jolyon FORD<sup>11</sup>, Ben W. MOL<sup>6,7</sup>, Susan P. WALKER<sup>1,3</sup>

<sup>1.</sup> *Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, VIC 3052, Australia*

<sup>2.</sup> *Reproductive Epidemiology Group, Murdoch Children's Research Institute, Parkville VIC 3052 Australia*

<sup>3.</sup> *Department of Obstetrics and Gynaecology, Mercy Hospital for Women, Mercy Health, Heidelberg VIC 3084 Australia*

<sup>4.</sup> *Department of Obstetrics and Gynaecology, The Northern Hospital, Northern Health, Epping VIC 3076 Australia*

<sup>5.</sup> *Center for Alcohol Policy Research (CAPR), La Trobe University, Bundoora VIC 3086 Australia*

<sup>6.</sup> *Department of Obstetrics and Gynaecology, Monash Health, Clayton VIC 3168*

<sup>7.</sup> *Department of Obstetrics and Gynaecology, Monash University, Clayton VIC 3168*

<sup>8.</sup> *Maternal-Fetal Medicine Department, Joan Kirner Women's and Children's Hospital, Western Health, St Albans VIC 3021 Australia*

<sup>9.</sup> *Department of Obstetrics and Gynaecology, the Royal Women's Hospital, Parkville VIC 3052 Australia*

<sup>10</sup> *Department of Obstetrics and Gynaecology, Box Hill Hospital, Eastern Health, Box Hill VIC*

*3128 Australia*

<sup>11</sup> *Department of Obstetrics and Gynaecology, Frankston Hospital, Peninsula Health VIC*

*3199, Australia*

<sup>12</sup> *Harvard School of Public Health, Harvard University, Cambridge MA, 02115 USA*

## **DISCLOSURES**

LH has received research funding from Ferring Pharmaceuticals outside the scope of this work. BWM is a consultant for Guerbet and has received research grants from Guerbet and Merck. KRP has received consultancy fees from Janssen. DLR has received fees from Alexion for participation in advisory boards unrelated to this work. All other authors declare no competing interests.

## **FUNDING**

This study was funded by the Norman Beischer Medical Research Foundation and the University of Melbourne Department of Obstetrics and Gynaecology. LH, BWM and KRP are supported by National Health and Medical Research Council investigator grants (GNT1196010, GNT11766437 and GNT2009765). The funding bodies had no role in any aspects of the design or conduct of this study.

## **PAPER PRESENTATION**

The findings of this study were submitted as a free communication for the Annual Scientific Meeting of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists at the Gold Coast, QLD, Australia in October 2022.

**CORRESPONDING AUTHOR:** A/Prof Lisa Hui

Dept of Perinatal Medicine, Level 3, Mercy Hospital for Women

163 Studley Rd, Heidelberg, VIC 3084 Australia

[lisa.hui@unimelb.edu.au](mailto:lisa.hui@unimelb.edu.au) fx. 61 3 8458 4504. Ph. 61 3 8458 4248

**WORD COUNT:** Abstract 494 words, Main manuscript 3616 words

## **CONDENSATION**

Stillbirths, spontaneous and iatrogenic preterm births significantly lower in COVID-19 vaccinated women

## **SHORT TITLE**

Reduction in stillbirth and preterm birth in COVID-19 vaccinated women

## **AT A GLANCE**

### **Why was this study conducted?**

- ② COVID-19 infection in pregnancy is associated with a higher risk of progression to severe disease, but vaccine uptake by pregnant women is hindered by persistent safety concerns. COVID-19 vaccination in pregnancy has been shown to reduce stillbirth, but its relationship with preterm birth is uncertain.
- ② Most of the published literature on COVID-19 vaccination in pregnancy have methodological limitations including fixed cohort bias and time-varying exposure.

- ② We conducted this multicenter study to provide robust evidence on mRNA COVID-19 vaccination and perinatal outcomes including congenital anomalies, stillbirth, and preterm birth.

### **What are the key findings?**

- ② The adjusted odds of stillbirth, preterm birth, and neonatal intensive care admission were significantly reduced among infants born to COVID-19 vaccinated women compared with unvaccinated women. COVID-19 vaccination during pregnancy was not associated with an increase in congenital anomalies.
- ② Our results conclusively demonstrate a significant reduction in both spontaneous and iatrogenic preterm birth for vaccinated women
- ② Vaccinated women were significantly more likely to be older, nulliparous, non-smoking, not requiring an interpreter, residing in a higher socioeconomic postcode, and vaccinated against pertussis and influenza. There were also significant differences in vaccination rates by region of birth.

### **What does this study add to what is already known?**

- ② Our analysis confirmed a strong relationship between the COVID-19 mRNA vaccine and lower preterm births and stillbirths
- ② In addition to its impact on reducing severe COVID-19 illness, vaccination may be a proxy for other biological and social determinants of health among our pregnant population.

**Keywords:** Vaccination, Pregnancy outcome, stillbirth, COVID-19, premature birth, cohort studies

## **ABSTRACT (493 words)**

**Background:** COVID-19 infection in pregnancy is associated with a higher risk of progression to severe disease, but vaccine uptake by pregnant women is hindered by persistent safety concerns. COVID-19 vaccination in pregnancy has been shown to reduce stillbirth, but its relationship with preterm birth is uncertain.

**Objective:** The aim of this study was to investigate the sociodemographic characteristics associated with vaccine uptake in Melbourne, Australia, and to compare perinatal outcomes by vaccination status.

**Study design:** Retrospective multicenter cohort study in Melbourne following the national recommendations for mRNA COVID-19 vaccination during pregnancy in June 2021. Routinely collected data from all 12 public maternity hospitals in Melbourne were extracted on births  $\geq 20$  weeks' gestation from 1<sup>st</sup> July 2021 to 31 March 2022. Maternal sociodemographic characteristics were analyzed from the total birth cohort. Perinatal outcomes were compared between vaccinated and unvaccinated women for whom weeks 20-43 of gestation fell entirely within the 9-month data collection period. The primary outcome was the rate of congenital anomaly in singleton infants  $\geq 20$  weeks' gestation among women vaccinated during pregnancy. Secondary perinatal outcomes including stillbirth, preterm birth (spontaneous and iatrogenic), birthweight  $\leq 3^{\text{rd}}$  centile, and newborn intensive care unit admissions were examined for singleton infants  $\geq 24$  weeks' gestation without congenital anomalies. We calculated the adjusted odds ratio of congenital anomalies and perinatal outcomes among vaccinated versus unvaccinated women using inverse propensity score weighting regression adjustment with multiple covariates;  $p < 0.05$  was considered statistically significant.

**Results:** Births from 32,536 women were analyzed: 17,365 (53.4%) were vaccinated and 15,171 (47.6%) were unvaccinated. Vaccinated women were significantly more likely to be older, nulliparous, non-smoking, not requiring an interpreter, of higher socioeconomic status, and vaccinated against pertussis and influenza. Vaccination status also varied by region of birth: compared with women born in Australia, women born in South and Eastern Europe, the Middle East, Africa and Oceania had lower adjusted odds of vaccination. There was no significant increase in the rate of congenital anomalies or birth weight  $\leq 3^{\text{rd}}$  centile in vaccinated women. Vaccinated women were significantly less like to have an infant with a major congenital anomaly compared with the unvaccinated group (2.4% vs 3.0%, aOR 0.72, 95%CI 0.56-0.94,  $p=0.02$ ). This finding remained significant even when the analysis was restricted to women vaccinated before 20 weeks' gestation. Vaccinated women had a significantly lower rate of stillbirth (0.2% vs 0.8%, aOR 0.18, 95%CI 0.09-0.37,  $P < 0.001$ ). Vaccination was associated with a significant reduction in total preterm births  $< 37$  weeks (5.1% vs 9.2%, aOR 0.60, 95% CI 0.51-0.71,  $p < 0.001$ ), spontaneous preterm birth (2.4% vs 4.0%, aOR 0.73 95% CI 0.56-0.96,  $p=0.02$ ) and iatrogenic preterm birth (2.7% vs 5.2%, aOR 0.52, 95%CI 0.41-0.65,  $p < 0.001$ ).

## **Conclusions**

COVID-19 Vaccine coverage was significantly influenced by known social determinants of health, which is likely to influence the strong association between COVID-19 vaccination and lower risks of stillbirth and preterm birth. We did not observe any adverse impacts of vaccination on fetal growth or development.

## Introduction

Pregnancy is an independent risk factor for severe COVID-19 infection, associated with higher rates of maternal hospitalization, intensive care unit admission and mortality compared with nonpregnant adults.<sup>1</sup> COVID-19 infection during pregnancy also increases the risk of serious adverse perinatal outcomes, including stillbirth, preterm birth, Caesarean birth, and preeclampsia.

An effective vaccine against SARS-CoV2 became available globally from early 2021,<sup>2</sup> with the Australian roll-out commencing in March 2021.<sup>3</sup> By the end of 2021, vaccine uptake in the eligible Australian population was 85 per 100.<sup>4</sup> It is now well-established that the mRNA COVID-19 vaccine is safe and protective against severe COVID-19 disease in pregnancy,<sup>5-8</sup> but this confidence was not present at the launch of the vaccine program due to the exclusion of pregnant women from the early clinical trials.<sup>9</sup> It was not until 9<sup>th</sup> June 2021 that Australian health authorities changed their advice on vaccination in pregnancy from cautiously recommending deferral to the postpartum period, to clearly recommending vaccination with an mRNA vaccine during pregnancy.<sup>10</sup> The change in health advice was met with vaccine hesitancy among some pregnant Australian women, with common concerns including side effects of the vaccine for their newborn and a perception of inadequate safety information.<sup>11</sup> Vaccination was available free of charge through a range of public vaccination centres, general practitioners, and within the antenatal clinics in some maternity services. However due to supply shortages, pregnant women could not readily access the COVID-19 vaccine until late July 2021.

A recent systematic review and meta-analysis of 23 studies confirmed the effectiveness of the COVID-19 vaccine in pregnancy, as well as showing a significant reduction in stillbirth.<sup>12</sup> However, this study was inconclusive about the impact of COVID-19 vaccination on preterm

birth. The meta-analysis of the six studies that reported on preterm birth showed a non-significant relative reduction in preterm birth of 10%. Only two studies accounted for time-dependent exposures, that is, included adjustment for the fact that the vaccination occurred at various gestations.<sup>13</sup> Women vaccinated in late pregnancy are not at risk of very preterm birth, which skews the results towards fewer preterm births in the vaccinated group. Another limitation of the literature is failure to account for fixed cohort bias.<sup>14</sup> Fixed cohort bias occurs in retrospective cohorts that are defined by date of birth using calendar start and end dates. This has the effect of introducing both left fixed truncation bias (start of data collection occurs at a fixed date, but at variable gestations for each included pregnancy) and right censoring bias (otherwise eligible subjects are not included because their birth occurs after the study end date). When the exposure rate (i.e. vaccination) is higher at the end of the study period, this will have the effect of overestimating the preterm birth rate in the exposed group as term vaccinated pregnancies that deliver after the end of the cohort date will not be captured.

In Melbourne, Australia, data collection on maternal COVID-19 vaccination status was mandated by the Department of Health for all births from 1<sup>st</sup> July 2021. These vaccination data were collected by a collaboration of 12 Melbourne public maternity hospitals under a research protocol established to monitor the effect of the pandemic on clinical quality indicators.<sup>15</sup> Data from the Collaborative Maternity and Newborn Dashboard for the COVID-19 pandemic (CoMaND) project were used here to (i) analyse the sociodemographic factors associated with COVID-19 vaccine uptake and (ii) assess the perinatal outcomes associated with vaccination in pregnancy including preterm birth, stillbirth and congenital anomalies.

## **Materials and Methods**



## **Institutional Review Board approval**

This study was given ethical approval from the Human Research Ethics Committees of Austin Health (Ref. HREC/64722/Austin-2020) and Mercy Health (Ref. 2020-031).

## **Study population**

We extracted routinely collected data on births  $\geq 20$  weeks from all 12 public maternity hospitals in Melbourne from 1<sup>st</sup> July 2021 to 31<sup>st</sup> March 2022. Approximately 80% of all hospital births in Melbourne occur in these study sites. Births in exclusively private hospitals and planned home births outside of publicly funded homebirth programs were not captured. However, women planning a private hospital or home birth would typically be transferred to a public hospital if they were at risk of preterm birth  $<31$  weeks or required tertiary maternal-fetal medicine care.

## **Outcome measures**

Our analysis was performed with several denominator groups according to the outcomes of interest.

### **1) Total births cohort**

#### **Sociodemographic characteristics**

We used the total number of women giving birth from 1<sup>st</sup> July 2021 to 31 March 2022 to compare the characteristics of those with and without at least one dose of a COVID-19 vaccine before or during pregnancy. The characteristics included: maternal age, body mass index (BMI in  $\text{kg}/\text{m}^2$ ), smoking status, need for an English interpreter, maternal region of birth, socioeconomic status (assigned by residential postcode), parity, diabetes (none,

gestational, pre-existing, not tested), influenza vaccination status, pertussis vaccination status, plurality, gestation at first antenatal visit  $\leq 12$  weeks, and geographical remoteness.

### **Vaccination status by the week of birth**

To examine temporal patterns in the uptake of COVID-19 vaccine following the health authority recommendations, we measured the weekly proportion of births to women who had received one or more doses of the mRNA COVID-19 vaccine before or during pregnancy. Choropleth maps of socioeconomic index for areas (SEIFA) and vaccination rates were generated in Tableau™ (Version 2022.3).

### **2) Calculated LMP cohort**

We used the calculated week of last menstrual period (cLMP), rather than week of birth, to define the vaccine-exposed and unexposed groups to ensure that any woman birthing from 20 to 43 weeks' gestation would be captured in the birth data, thus avoiding 'fixed cohort bias'. We subtracted the infant's gestational age at birth in completed weeks from the week of birth to obtain the week of calculated LMP (cLMP). Using this cLMP, we defined a cohort containing women for whom weeks 20-43 of gestation would have occurred after mandatory vaccination status reporting commenced on 1st July 2021. This included women whose cLMP occurred during the 16 weeks from 11<sup>th</sup> February 2021 to 31<sup>st</sup> May 2021 inclusive (Figure 1).

The pregnancies for which weeks 20-43 of gestation would have occurred during the birth data collection period (1<sup>st</sup> July 2021 - 31 March 2022) were selected for the primary and secondary outcome analysis to avoid fixed cohort bias. Multifetal gestations and women

who had preconception COVID-19 vaccination only were excluded from the singleton cLMP cohort.

*Primary outcome: congenital anomalies  $\geq 20$  weeks*

The primary outcome was the rate of major congenital anomalies in singleton infants  $\geq 20$  weeks' gestation in women who had received at least one COVID-19 vaccination dose during pregnancy, including terminations of pregnancies.

*Secondary outcomes: perinatal outcomes  $\geq 24$  weeks*

Secondary outcomes were calculated from the singleton cLMP cohort, following exclusion of congenital anomalies, termination of pregnancies, and births  $< 24$  weeks gestation.

Secondary outcomes were calculated using 'all births' denominator (live births and stillbirths)

1. Stillbirths: total, term, and preterm  $< 37$  weeks
2. Preterm birth  $< 37$  weeks: total, spontaneous, and iatrogenic. An iatrogenic birth was defined as any birth without spontaneous onset of labor (i.e. induced labor or no labor).
3. Fetal growth restriction (FGR): defined as birthweight  $\leq 3^{\text{rd}}$  centile using Australian population sex-specific birth weight charts.<sup>16</sup>
4. Apgar score  $< 7$  at five minutes
5. Special care nursery (SCN) admission
6. Neonatal intensive care unit (NICU) admission

7. Mode of birth: induction of labor, pre-labor Cesarean birth, Cesarean birth after labor onset, unassisted vaginal birth, instrumental vaginal birth (forceps/vacuum),
8. Born before arrival. This refers to the rate of planned hospital births that occur before arrival, including unplanned births at home, in transit, or other locations
9. Severe postpartum hemorrhage: estimated blood loss  $\geq 1000$ ml
10. Iatrogenic birth for fetal compromise: total,  $\geq 37$  weeks,  $< 37$  weeks. An iatrogenic birth was an induction of labor or Cesarean birth prior to labor onset. Indications for induction of labor and Cesarean births were coded according to the Australian Institute of Health and Welfare Metadata Online Registry, which defines fetal compromise as “suspected or actual fetal compromise, and intrauterine growth restriction”.<sup>17</sup> Any documentation of suspected fetal growth restriction, antepartum abnormal cardiotocography, “fetal distress” (without labor), reduced fetal movements, oligohydramnios, abnormal umbilical artery Doppler studies, or placental insufficiency were included in this classification.

All secondary outcomes, other than the outcomes of congenital anomalies and stillbirths, were also calculated using live births as the denominator. Iatrogenic births for fetal compromise were only calculated using the live births denominator.

COVID-19 infections during pregnancy were collected and analyzed for the main outcomes of congenital anomalies, stillbirth and preterm birth according to vaccination status.

### **Statistical analysis**

No sample size calculation was performed as this was a cohort defined by the vaccination era period. Analyses of secondary outcomes were considered exploratory and no

adjustments for multiple comparisons were made. Continuous variables in both determinants and safety analyses were presented with mean and standard deviation (SD). Categorical variables were presented as count and percentages. Statistical analyses were conducted using Stata 17 (StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC), and two-sided p-values below 0.05 were considered statistically significant.

### **Determinants of COVID-19 vaccination uptake**

We performed multiple imputations by chained equation (MICE) to minimise the bias from missing data in our dataset and created five imputed datasets. Factors associated with antenatal COVID-19 vaccination were analyzed using multivariable Poisson regression with covariates selected based on subject matter knowledge. Results of the regression analyses were presented as Incident Rate Ratio (IRR). The hospital-specific rates of vaccination uptake were summarised and reported as forest plots.

### **Perinatal outcomes**

We used inverse-probability-weighted-regression-adjustment (IPTWRA) of Stata 'teffects' suite of commands to balance the baseline difference in the population by COVID-19 vaccination status. The IPTWRA also accounts for the missing data. We adjusted for the following covariates: maternal age, body mass index (BMI) at first antenatal visit, maternal region of birth, need for interpreter (proxy indicator for primary language and categorised as yes or no), parity, socioeconomic status (using quintiles of SocioEconomic Index for Areas, SEIFA for maternal postcode), diabetes status (non, gestational, pre-existing, not tested), and smoking in pregnancy status. These covariates were chosen using subject

matter knowledge. Adjusted analyses were performed using logistic regression and presented as Odds Ratios (OR).

### *Sensitivity analyses*

We performed unadjusted and adjusted logistic regression analysis without IPTWRA to check the consistency of the directions of associations between COVID-19 vaccination and maternal and perinatal outcomes.

We performed a sensitivity analysis for congenital anomalies by excluding women who were first vaccinated  $\geq 20$  weeks, as the biologically relevant period of exposure for teratogenesis is in early pregnancy.

To examine the impact of time-varying exposure and the ‘healthy vaccinee’ effect on preterm birth and stillbirth, we performed a Cox regression analysis excluding women who received their first dose of COVID-19 vaccine  $\geq 24$  weeks gestation and adjusted for pertussis vaccination status. We used Kaplan-Meier curves to plot the cumulative hazard of the outcomes of interest. The proportionality of the hazards of control and exposed cohorts was tested using Schoenfeld residuals.

## **Results**

There were 33,018 infants born to 32,536 women during the study period. The numbers of inclusions and exclusions for the various cohorts are shown in the study flowchart in Figure 2. The weekly percentage of births to vaccinated women are shown in Figure 3. By the end of the study period 85% of women giving birth had received at least one dose of the COVID-19 vaccine before or during pregnancy (Figure 3).

The weekly percentage of births to women with COVID-19 infection during pregnancy are shown in Figure 4, representing a cumulative total of 1078 infected women. By the end of March 2022, 13% of women giving birth had experienced a COVID-19 infection during their pregnancy.

### **Sociodemographic characteristics of vaccinated vs unvaccinated groups**

Of the 32,536 women giving birth during the 9-month study period, 17,365 (53.4%) had received at least one dose of the mRNA COVID-19 vaccine and 15,171 (46.6%) had not. The characteristics of vaccinated and unvaccinated groups are shown in Table 1. Vaccinated women were significantly older, and more often nulliparous, non-smoking, not requiring an interpreter, of higher socioeconomic status, and vaccinated against pertussis and influenza. Vaccination status also varied by region of birth. Women from the Middle East, North Africa, Southern and Eastern Europe, and Oceania were less likely to be vaccinated than Australian-born women; women born in Southeast Asia were significantly more likely to be vaccinated. Choropleth maps of postcodes showing socioeconomic status and vaccination coverage are shown in Figure 5. The Forest plot of vaccination coverage by hospitals are provided in Figure 6.

### **Perinatal outcomes in the cLMP cohort**

After exclusions, 12,679 births remained in the cLMP cohort (Figure 2). Of these, 9927 had received at least one dose of the COVID-19 vaccination during pregnancy. A documented gestation at first and second vaccine dose was available for 98.3% and 92.7% of the vaccinated groups respectively. The median gestational age at the first dose was 24 weeks

(interquartile range 19-28 weeks) and 28 w (interquartile range 24-32 weeks) for the second dose (Figure 7).

The primary and secondary outcomes with 'all births', and 'live births' denominators are presented in Tables 2 and 3 respectively.

### **Primary outcome**

#### *Congenital anomalies*

The rate of major congenital anomalies was significantly lower in the vaccinated group than in the unvaccinated group (2.4% vs 3.0%, aOR 0.72, 95%CI 0.56-0.94,  $p=0.02$ ) (Table 2). This did not remain statistically significant in the sensitivity analysis that excluded women vaccinated  $\geq 20$  weeks' gestation, though the direction of the trend was similar (2.6% vs 3.0%, aOR 0.80, 95%CI 0.57-1.13,  $p=0.21$ ) (Table 4).

### **Secondary outcomes**

The vaccinated group had a significantly lower rate of stillbirth than the unvaccinated group (0.2% vs 0.8%, aOR 0.18, 95%CI 0.09-0.37,  $P < 0.001$ )(Table 2). When stratified by gestational age, this difference was statistically significant only for preterm stillbirths (0.1% vs 0.7%, aOR 0.12, 95%CI 0.05-0.31,  $p < 0.001$ ). This finding remained robust in the sensitivity analysis (Table 4).

The vaccinated group also had a significantly lower rate of preterm birth (5.1% vs 9.2%, aOR 0.60, 95%CI 0.51-0.71,  $p < 0.001$ ), which was significant for both spontaneous preterm birth (2.4% vs 4.0%, aOR 0.73, 95% 0.56-0.96,  $P=0.02$ ) and iatrogenic preterm birth (2.7% vs 5.2%, aOR 0.52, 95%CI 0.41-0.65,  $P < 0.001$ ). These findings remained robust in the sensitivity analysis (Table 4). The hazard ratio plots for preterm birth and stillbirths that excluded



women vaccinated  $\geq$  24 weeks and adjusted for pertussis vaccination status are shown in Figure 8.

There was also a significant reduction in admissions to NICU in the vaccinated group (2.4% vs 4.1%, aOR 0.70, 95%CI 0.53-0.91, P= 0.007). This trend to lower NICU admissions was observed in the sensitivity analysis, but with a p value > 0.05.

There was no difference in the rate of severe fetal growth restriction between the vaccinated and unvaccinated groups. The vaccinated group had a significantly higher rate of induction of labor and iatrogenic births for fetal compromise at term gestation, but significantly lower rate of iatrogenic birth for fetal compromise at preterm gestations and lower rate of pre-labor Cesarean births (Table 3). There was no significant difference in other birth outcomes, such as PPH, vaginal births, or births before arrival to hospital.

#### *Subgroup analysis of stillbirth and preterm birth by COVID-19 infection during pregnancy and vaccination status*

There were 1,078 women with a COVID-19 infection during pregnancy in the total study cohort; of these, 518 women were in the cLMP cohort (Table 5). The crude OR of COVID-19 infection was significantly lower in the vaccinated group (3.6% vs 5.9%, OR 0.59, 95%CI 0.49-0.71, p < 0.0001). There was also a significant reduction in preterm birth among COVID-19 infected women who had been vaccinated during pregnancy (2.3% vs 7.0%, OR 0.32, 95% CI 0.12-0.80, p=0.015) (Table 5). The number of infected cases was too low to allow adjustment for covariates.

## **Comment**

### *Principal findings*

Our multicenter cohort study confirms the safety and benefits of COVID-19 vaccination in pregnancy and adds new insights into the relationship between vaccination and preterm birth. Vaccinated women did not have higher rates of congenital anomalies or fetal growth restriction, but had significantly lower rates of stillbirth and preterm birth compared with unvaccinated women. Of note, our study shows that COVID-19 vaccination during pregnancy is associated with significantly lower rates of both spontaneous and iatrogenic preterm birth, even after excluding women vaccinated  $\geq 24$  weeks' gestation.

### *Results in the Context of What is Known*

Our finding on congenital anomalies provides additional reassuring safety data on COVID-19 vaccination in pregnancy. We have strengthened the existing evidence base by showing that there was no increase in the rate of congenital anomalies for women vaccinated before 20 weeks' gestation, when the risk of teratogenesis would be expected to be higher.

The significant reduction in stillbirths is in keeping with previously published studies, but our results are remarkable for the magnitude of the effect size. Our aOR of 0.18 is much lower than any of the seven individual studies included in the recent meta-analysis, which reported ORs of 0.50-1.50.<sup>12</sup> This effect was even more profound in the preterm stillbirths, where vaccination was associated with a 1 in 1,000 of risk preterm stillbirth compared with 7 in 1,000 without vaccination.

That vaccination reduces stillbirth makes biological sense given the strong association between severe COVID-19 infection and an increased risk of stillbirth.<sup>1</sup> However, as an observational study, we can only infer a causal relationship between vaccination and fewer

stillbirths, presumably mediated by the significant reduction in the odds of COVID-19 infection. However, the burden of COVID-19 infection in the unvaccinated cohort did not appear high enough to account for the entire effect of vaccination on stillbirths. Although we controlled for multiple covariates, and performed a sensitivity analysis on pertussis vaccination status, we speculate that other relevant unmeasured factors associated with COVID-19 vaccination persist, such as health literacy or healthcare-seeking behavior (the ‘healthy vaccinee’ bias).<sup>18</sup> The significantly higher rates of term induction of labor and better adherence to universal gestational diabetes screening in the vaccinated group suggest important variations in obstetric care that may have contributed to the difference in perinatal outcomes.

Our study provides the strongest evidence to date to support the association between COVID-19 vaccination and reduction in iatrogenic and spontaneous preterm births. The reduction in iatrogenic preterm birth may be due to prevention of complications directly related to COVID-19 infection such as preeclampsia, or severe maternal respiratory morbidity, while the reduction in spontaneous preterm birth may be related to avoiding the systemic inflammation associated with COVID-19 infection or other non-specific immune effects. Furthermore, unmeasured confounders may also be responsible for the reduction in preterm births, as discussed above for stillbirths.

The sociodemographic characteristics of our unvaccinated cohort mirror the findings from the UK showing variation in vaccination uptake by socioeconomic status, age, and region of birth.<sup>19</sup> In multicultural Melbourne, public health messaging to non-English speaking communities had notable flaws, including incorrect and out-of-date translations of vaccine communications.<sup>21</sup> This may have contributed to a lack of access to accurate vaccine safety information and a lack of trust in the health authorities among certain ethnic groups.

### *Clinical implications*

Our data gives us strong evidence to confidently endorse the safety of the mRNA vaccine for our local pregnant population and to promote the benefits of reduced stillbirth and preterm birth. Our vaccine coverage of 85% at the end of March 2022 is an achievement that surpasses those recorded in the United States and the United Kingdom (70% and 60% respectively in 2022).<sup>19,21</sup> However, the substantial regional variation in vaccine coverage within Melbourne (Figure 6) reflects the socioeconomic and cultural diversity of our population. A sensitive, multifaceted approach in partnership with community leaders is required to improve public health communication and remove barriers to vaccination uptake.<sup>22</sup>

### *Research implications*

The significant reduction in stillbirth and preterm birth raises research questions that may lead to improved care outside the pandemic. Biological and social factors responsible for the reduction in spontaneous preterm birth should be investigated, including nonspecific inflammatory-mediated mechanisms for preterm birth and the mitigating effects of vaccination for COVID-19 and other diseases.

It is also likely that vaccination status is a proxy for unmeasured social determinants of health, in addition to the well-established demographic factors included in our analysis. This ‘healthy vaccinee bias’ may reflect the quality of relationship between a pregnant woman and her health care provider, as personal recommendation by a health care practitioner remains one of the most important influences on vaccine uptake.<sup>11</sup> It is also correlated with trust in the government.<sup>23</sup> Understanding these confounders and developing new metrics to capture them would aid future studies of vaccination in pregnancy and perinatal outcomes.

### *Strengths and limitations*

Our large multicenter cohort of all public hospitals captured 80% of total births in Melbourne, including all hospitals that were designated by the government to care for COVID-19 pregnant inpatients. The major strengths of our cohort are its size, timeliness of data collection, avoidance of common methodological biases, and detailed individual patient level data including gestation at first vaccine dose.

### *Limitations*

This was a retrospective study using routinely collected maternity data. Only data on first and second doses of COVID-19 vaccine were collected by hospitals during the study period, so the uptake of the third dose by pregnant women is unknown. The 1078 women with COVID-19 infection in the total cohort should be considered a minimum estimate of our total COVID-19 caseload. We do not have individual medical record data to determine whether the stillbirths and preterm births in the unvaccinated cohort were the direct result of acute COVID-19 disease. We await the outcomes from the CHOPAN registry for detailed local information on pregnancy outcomes for women with COVID-19.<sup>24</sup>

Our maternity data collection only includes birth outcomes from 20 weeks' gestation. We therefore cannot comment on risk of miscarriage after COVID-19 vaccination, although other large studies have already provided reassuring data on this.<sup>25,26</sup> We acknowledge that our findings on the risk of congenital anomalies are limited by the lack of data on early pregnancy. The lower rate of congenital anomalies observed in the vaccinated group may be a result of differences in utilization of aneuploidy screening, ultrasound scans, and termination of pregnancy for fetal abnormality before 20 weeks. There may have also been a true reduction in the prevalence of congenital anomalies in the vaccinated group due to

differences in periconceptional health behaviors, such as the use of folic acid supplementation, pre-conception optimization of medical conditions, avoidance of teratogens, and dietary quality.<sup>27</sup>

## **Conclusions**

COVID-19 vaccination during pregnancy is strongly associated with lower risks of stillbirth and preterm birth, without any adverse impacts on fetal growth or development. Vaccine coverage was not distributed equally in our population and was significantly influenced by known social determinants of health. Our findings highlight both the achievements of our vaccination program and the challenges for maternity care in ensuring equity of health outcomes across our population.

## **Contributors**

LH, SW, JS, CW, DR, BM, KP and SP conceived of the original collaboration, LH designed, coordinated, and acquired funding for the study; LH and MM drafted the data analysis plan, and all authors edited and/or approved the analysis plan; LH, SP, JS, DR, CW, PS, JF, MM collected the primary data; MM performed the data cleaning and coding; LH, MM and DR performed the data analysis; MM and LH created the tables and figures; LH and MM wrote the primary manuscript; all authors reviewed and edited the draft manuscript for scientific content and approved the final submitted manuscript.

## **Funding**

This study was funded by the Norman Beischer Medical Research Foundation and the University of Melbourne Department of Obstetrics and Gynaecology. LH, KRP and BWM are

supported by National Health and Medical Research Council investigator grants (GNT1196010, GNT2009765 and GNT11766437). The funding bodies had no role in any aspects of the design or conduct of this study.

### **Disclosures**

LH has received research funding from Ferring Pharmaceuticals outside the scope of this work. BWM is a consultant for Guerbet, and has received research grants from Guerbet and Merck. KRP has received consultancy fees from Janssen. DLR has received fees from Alexion for participation in advisory boards unrelated to this work. All other authors declare no competing interests.

### **Data sharing**

Non-identifiable individual participant data is available on request to the Austin Health Human Research Ethics Committee ([ethics@austin.org.au](mailto:ethics@austin.org.au)) and the Mercy Health Human Research Ethics Committee ([ethics@mercy.com.au](mailto:ethics@mercy.com.au)). The study investigators may contribute aggregate and non-identifiable individual patient data to national and international collaborations whose proposed use of the data has been ethically reviewed and approved by an independent committee and following signing of an appropriate research collaboration agreement with the University of Melbourne.

### **Acknowledgements**

The health services and individual hospitals contributing to the Collaborative Maternity and Newborn Dashboard for COVID-19 pandemic are:

- ☐ Mercy Health (Mercy Hospital for Women, Werribee Mercy Hospital)

- ② The Royal Women’s Hospital, The Women’s at Sandringham
- ② Monash Health (Monash Medical Center, Casey Hospital, Dandenong Hospital)
- ② Northern Health (The Northern Hospital)
- ② Western Health (Joan Kirner Women’s and Children’s Hospital)
- ② Eastern Health (Box Hill Hospital, The Angliss Hospital)
- ② Peninsula Health (Frankston Hospital)

We thank the health service data managers and research midwives (Tania Fletcher, Lynn Rigg, Michelle Knight, Eleanor Johnson, Abby Monaghan, Pauline Hamilton, Roshanee Perera) for their assistance with primary data collection and Mr Andrew Goldsachs for assistance with coding of the indications for iatrogenic births.

## References

1. Villar J, Ariff S, Gunier RB, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. *JAMA Pediatr.* 2021;175(8):817-826.
2. Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.
3. Australian Department of Health. COVID-19 vaccine rollout update – 30 April 2021. Accessed on 21 May 2022 at <https://www.health.gov.au/sites/default/files/documents/2021/04/covid-19-vaccine-rollout-update-30-april-2021.pdf>
4. World Health Organization COVID-19 Vaccination Dashboard. Accessed on 22 May at <https://app.powerbi.com/view?r=eyJrIjojMWVjNzZkNjctZTNiNy00YmMzLTkxZjQ0NmJiZD>



M2MTYxNzEwliwidCI6ImY2MTBjMGI3LWJkMjQtNGlzOS04MTBiLTNkYzI4MGFmYjU5MCI  
sImMiOjh9

5. Shimabukuro TT, Kim SY, Myers TR, et al; CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021; 384(24):2273-2282.
6. de Freitas Paganoti C, Alkmin da Costa R, T. Papageorghiou A, et al. COVID-19 Vaccines Confer Protection in Hospitalized Pregnant and Postpartum Women with Severe COVID-19: A Retrospective Cohort Study. Vaccines. 2022; 10(5):749.  
<https://doi.org/10.3390/vaccines10050749>
7. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021;225(3):303.e1-303.e17.
8. Kalafat E, Heath P, Prasad S, O'Brien P, Khalil A. COVID-19 vaccination in pregnancy. Am J Obstet Gynecol. 2022 May 11:S0002-9378(22)00364-7. doi: 10.1016/j.ajog.2022.05.020.  
Epub ahead of print.
9. UKOSS NPEU Surveillance reports COVID-19 Vaccination in Pregnancy (2021)  
<https://www.npeu.ox.ac.uk/ukoss/completed-surveillance/covid-19-vaccination-in-pregnancy>
10. Joint statement between RANZCOG and ATAGI about COVID-19 vaccination for pregnant women June 9 2021. <https://www.health.gov.au/news/joint-statement-between-ranzcog-and-atagi-about-covid-19-vaccination-for-pregnant-women>
11. Ward C, Megaw L, White S, Bradfield Z. COVID-19 vaccination rates in an antenatal population: A survey of women's perceptions, factors influencing vaccine uptake and potential contributors to vaccine hesitancy. Aust N Z J Obstet Gynaecol. 2022. doi: 10.1111/ajo.13532. Epub ahead of print.

12. Prasad S, Kalafat E, Blakeway H, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. *Nat Commun.* 2022;13(1):2414. doi: 10.1038/s41467-022-30052-w.
13. Barnett AG. Time-dependent exposures and the fixed-cohort bias. *Environ Health Perspect.* 2011;119(10): A422-A423.
14. Strand LB, Barnett AG, Tong S. Methodological challenges when estimating the effects of season and seasonal exposures on birth outcomes. *BMC Med Res Methodol.* 2011;11:49.
15. Hui L, Marzan MB, Potenza S, et al. Collaborative maternity and newborn dashboard (CoMaND) for the COVID-19 pandemic: a protocol for timely, adaptive monitoring of perinatal outcomes in Melbourne, Australia. *BMJ Open.* 2021;11(11):e055902.
16. Dobbins TA, Sullivan EA, Roberts CL, Simpson JM. Australian national birthweight percentiles by sex and gestational age, 1998-2007. *Med J Aust.* 2012;197(5):291-4.
17. Australian Institute of Health and Welfare Metadata Online Registry (METeOR). <https://meteor.aihw.gov.au/content/index.phtml/itemId/587046> (accessed 5 August 2021)
18. Renschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. *BMC Infect Dis.* 2015; 15:429.
19. UK Health Security Agency COVID-19 vaccine surveillance report Week 19. 12 May 2022. Accessed on 22 May 2022 at: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1075115/COVID-19\\_vaccine\\_surveillance\\_report\\_12\\_May\\_2022\\_week\\_19.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1075115/COVID-19_vaccine_surveillance_report_12_May_2022_week_19.pdf)

20. ABC News. Australia's official COVID-19 health information translations left to become eight weeks out of date. 12 August 2021. Accessed on 21 May 2022 at: [https://www.abc.net.au/news/2021-08-12/covid-19-information-weeks-out-of-date/100369794?utm\\_campaign=abc\\_news\\_web&utm\\_content=link&utm\\_medium=content\\_shared&utm\\_source=abc\\_news\\_web](https://www.abc.net.au/news/2021-08-12/covid-19-information-weeks-out-of-date/100369794?utm_campaign=abc_news_web&utm_content=link&utm_medium=content_shared&utm_source=abc_news_web)
21. CDC COVID data tracker. Accessed on 22 May 2022 at: <https://covid.cdc.gov/covid-data-tracker/#vaccinations-pregnant-women>
22. Moderator:, Hui L; Experts:, Knight M, Edlow A, Homer C, Danchin M. Pregnancy in the Time of COVID-19: What Are the Challenges for Maternity Care? Clin Chem. 2022;68(3):385-391.
23. Trent M, Seale H, Chughtai AA, Salmon D, MacIntyre CR. Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the United States, United Kingdom, and Australia. Vaccine. 2022;40(17):2498-2505.
24. Coronavirus Health Outcomes in Pregnancy and Newborns (CHOPAN) registry. Australian and New Zealand Clinical Trials Registry. Available at: <https://chopan.psanz.com.au/chopan/>. Accessed 22 May 2022.
25. Magnus MC, Gjessing HK, Eide HN, Wilcox AJ, Fell DB, Håberg SE. Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage. N Engl J Med. 2021; 385(21):2008-2010.
26. Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, Petersen EE, Ju J, Beauregard J, Wilcox AJ, Rose CE, Meaney-Delman DM, Ellington SR; CDC v-safe Covid-19 Pregnancy Registry Team. Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion. N Engl J Med. 2021;385(16):1533-1535.

27. Yee LM, Silver RM, Haas DM, Parry S, Mercer BM, Iams J, Wing D, Parker CB, Reddy UM, Wapner RJ, Grobman WA. Quality of periconceptional dietary intake and maternal and neonatal outcomes. *Am J Obstet Gynecol.* 2020; 223(1):121.e1-121.e8.

Table 1. Maternal characteristics by COVID-19 vaccination status among total births cohort

Maternal characteristics	Vaccinated N=17,365		Unvaccinated N=15,171		Multiple imputed dataset		
	n	%	n	%	Denominator	IRR*	P-value
<b>Maternal age group, years</b>							
<25	1,477	8.5	1,915	12.6	32,536	0.91	0.005
25-29	3,223	18.6	3,377	22.3		Ref	
30-34	7,224	41.6	5,823	38.4		1.12	<0.001
35-39	4,487	25.8	3,327	21.9		1.18	<0.001
≥ 40	954	5.5	729	4.8		1.19	<0.001
<b>Parity</b>							
0	7,783	44.8	6,259	41.3	32,535	1.09	<0.001
1 or more	9,582	55.2	8,911	58.7		Ref	
<b>Plurality</b>							
Singleton	17,102	98.5	14,936	98.5	32,536	Ref	
Multifetal pregnancy	263	1.5	235	1.6		1.00	0.96
<b>BMI Categories</b>							
<18	193	1.2	173	1.2	30,824	0.99	0.90
18-24	7,651	46.3	6,477	45.3		Ref	
25-29	4,892	29.6	4,322	30.0		1.00	0.97
30-34	2,228	13.5	1,950	13.6		1.03	0.27
35-39	947	5.7	860	6.0		1.04	0.26
≥40	603	3.7	528	3.7		1.08	0.092
<b>Smoking in pregnancy</b>							
Non-smokers	16,883	97.2	14,270	94.1	32,536		
Smokers	482	2.8	901	5.9		0.71	<0.001
<b>Region of Birth</b>							
Americas	317	1.8	209	1.4	32,352	1.05	0.37
Australia	8,916	51.7	7,898	52.3		Ref	
North Africa and Middle East	661	3.8	829	5.5		0.89	0.005
Northeast Asia	600	3.5	447	3.0		1.01	0.76
Northwest Europe	616	3.6	373	2.5		1.09	0.050
Oceania	527	3.2	633	4.2		0.90	0.018
Southeast Asia	1,525	8.8	1,042	6.9		1.12	<0.001
Southern and Central Asia	3,426	19.9	2,758	18.3		1.03	0.17
Southern and Eastern Europe	249	1.4	390	2.6		0.71	<0.001
Sub-Saharan Africa	426	2.5	510	3.4		0.89	0.022
<b>Interpreter required</b>							
Non-required	16,645	95.9	14,413	95.0	32,536		
Required	720	4.2	758	5.0		0.96	0.27
<b>SEIFA quintile</b>							
1 - Most disadvantaged	3,288	19.1	3,551	23.7	32,181	0.94	0.005
2	2,466	14.4	2,223	14.8		1.00	0.96
3	4,283	24.9	3,899	26.0		Ref	
4	3,980	23.2	3,124	20.8		1.05	0.039
5 - Most advantaged	3,159	18.4	2,208	14.7		1.07	0.007

<b>Remoteness of residence</b>							
Regional	304	1.8	358	2.4	32,536	Ref	
Metropolitan Location	17,061	98.3	14,813	97.6		0.93	0.19
<b>Gestation at first antenatal visit</b>							
≤ 12 weeks	12,252	70.6	10,656	70.2	32,536	Ref	
>12 weeks	5,113	29.4	4,515	29.8		0.99	0.58
<b>Antenatal Influenza Vaccine</b>							
Non-vaccinated	3,815	22.2	4,899	32.9	32,081	Ref	
Vaccinated	13,362	77.8	10,005	67.1		1.24	<0.001
<b>Antenatal Pertussis Vaccine</b>							
Non-vaccinated	1,415	8.2	3,114	20.8	32,280	Ref	
Vaccinated	15,860	91.8	11,891	79.3		1.74	<0.001
<b>Diabetes Mellitus</b>							
None	13,012	75.0	11,555	76.2	32,527	Ref	
Gestational diabetes mellitus	4,088	23.6	3,299	21.8		1.03	0.10
Pre-existing diabetes mellitus	197	1.1	143	0.9		1.10	0.17
Not tested for gestational diabetes mellitus	64	0.4	169	1.1		0.61	<0.001

BMI, body mass index; SD, standard deviation; SEIFA, socioeconomic index for areas; w, weeks;

Table 2. Primary and secondary outcomes among all births (live births and stillbirths)

Primary and secondary outcomes	Vaccinated		Unvaccinated		Unadjusted Odds Ratio (IPTWRA)				Adjusted Odds Ratio (IPTWRA)			
	n	(%)	n	(%)	OR	L	U	P value	aOR	L	U	P value
Singleton cLMP cohort $\geq$ 20 weeks	N=9927		N=2752									
Congenital anomalies	236	2.4	83	3.0	0.79	0.62	1.01	0.06	0.72	0.56	0.94	0.02
Singleton cLMP cohort excluding congenital anomalies, TOP, and births < 24 weeks	N=9682		N=2607									
Stillbirths												
Stillbirths	15	0.2	21	0.8	0.19	0.10	0.37	0.00	0.18	0.09	0.37	<0.001
Stillbirths >37 weeks	6	0.1	3	0.1	0.54	0.13	2.15	0.38	0.38	0.09	1.55	0.18
Stillbirths <37 weeks	9	0.1	18	0.7	0.13	0.06	0.30	0.00	0.12	0.05	0.31	<0.001
Preterm birth <37 weeks												
Total	495	5.1	239	9.2	0.56	0.48	0.65	0.00	0.60	0.51	0.71	<0.001
Spontaneous	234	2.4	104	4.0	0.61	0.48	0.76	0.00	0.73	0.56	0.96	0.02
Iatrogenic	261	2.7	135	5.2	0.52	0.42	0.64	0.00	0.52	0.41	0.65	<0.001
Newborn Outcomes												
Fetal growth restriction	237	2.5	63	2.4	1.01	0.77	1.33	0.93	1.07	0.79	1.44	0.68
SCN admission	907	9.4	281	10.8	0.87	0.77	0.99	0.03	0.92	0.80	1.06	0.27
NICU admission	236	2.4	106	4.1	0.60	0.48	0.75	0.00	0.70	0.53	0.91	0.01
Apgars < 7 at 5 minutes	170	1.8	80	3.1	0.57	0.44	0.74	0.00	0.72	0.51	1.01	0.06
Intrapartum outcomes												
Induction of labor	3589	37.1	835	32	1.16	1.09	1.23	0.00	1.11	1.04	1.18	0.001
Unassisted Vaginal Births	4,738	48.9	1,378	52.9	0.93	0.89	0.97	0.00	0.98	0.94	1.02	0.38
Instrumental Vaginal Births	1,533	15.8	338	13.0	1.22	1.09	1.36	0.00	1.08	0.96	1.21	0.22
Cesarean birth - no onset of labor	1,829	18.9	529	20.3	0.93	0.85	1.02	0.11	0.90	0.81	0.99	0.04
Cesarean birth - after onset of labor	1,583	16.4	360	13.8	1.18	1.06	1.32	0.00	1.07	1.07	1.21	0.27
Born before arrival	62	0.6	27	1.0	0.62	0.39	0.97	0.04	0.81	0.50	1.31	0.39
Severe PPH $\geq$ 1000ml	806	8.3	205	7.9	1.06	0.91	1.23	0.45	0.97	0.83	1.13	0.72

\*adjusted for maternal age, metropolitan vs regional residence, smoking status, need for interpreter, body mass index, region of birth, socioeconomic index for postcodes, diabetes mellitus, parity, infant sex, gestation at first antenatal visit

aOR, adjusted odds ratio; cLMP, calculated last menstrual period; IPTWRA, inverse proportionality treatment weighted regression adjustment; L, lower limit of 95% confidence interval; SCN, special care nursery; NICU, neonatal intensive care unit; OR, odds ratio; PPH, postpartum hemorrhage; TOP, termination of pregnancy; U, Upper limit of 95% confidence interval

Table 3. Secondary outcomes among live births

Singleton cLMP cohort excluding congenital anomalies, TOP, births < 24 weeks and stillbirths	Vaccinated N=9667		Unvaccinated N=2586		Unadjusted Odds Ratio (IPTWRA)				Adjusted Odds Ratio* (IPTWRA)			
	n	(%)	n	(%)	OR	L	U	P value	aOR	L	U	P value
<b>Preterm birth &lt;37 weeks</b>												
Total	486	5.0	221	8.6	0.59	0.50	0.69	<0.001	0.64	0.54	0.76	<0.001
Spontaneous	230	2.4	102	3.9	0.60	0.48	0.76	<0.001	0.72	0.55	0.94	0.017
Iatrogenic	256	2.7	119	4.6	0.58	0.47	0.71	<0.001	0.58	0.46	0.74	<0.001
<b>Newborn Outcomes</b>												
Fetal growth restriction	236	2.4	62	2.4	1.02	0.77	1.34	0.899	1.08	0.79	1.46	0.63
SCN admission	907	9.4	281	10.9	0.86	0.76	0.98	0.023	1.08	0.80	1.06	0.27
NICU admission	236	2.4	106	4.1	0.60	0.48	0.75	<0.001	0.69	0.53	0.91	0.01
Apgars < 7 at 5 minutes	155	1.6	60	2.3	0.69	0.51	0.93	0.013	1.39	0.51	1.01	0.06
<b>Intrapartum outcomes</b>												
Induction of labor	3,584	37.1	820	31.7	1.17	1.10	1.24	<0.001	1.12	1.05	1.19	0.001
Cesarean birth - no onset of labor	1,826	18.9	526	20.3	0.93	0.85	1.01	0.094	0.90	0.81	0.99	0.04
Unassisted Vaginal Births	4,728	48.9	1,360	52.6	0.93	0.89	0.97	0.001	0.99	1.06	1.03	0.50
Instrumental Vaginal Births	1,531	15.8	338	13.1	1.21	1.09	1.35	0.001	1.07	0.95	1.20	0.27
Cesarean birth - after onset of labor	1,583	16.4	360	13.9	1.18	1.06	1.31	0.003	0.30	0.94	1.20	0.30
Born before arrival	61	0.6	26	1.0	0.63	0.40	0.99	0.046	0.83	0.51	1.35	0.45
Severe PPH ≥ 1000ml	805	8.3	205	7.9	1.05	0.91	1.22	0.512	0.96	0.83	1.13	0.64
<b>Iatrogenic births for fetal compromise</b>												
Iatrogenic birth for fetal compromise	1,853	19.17	451	17.44	0.46	0.34	0.64	0.00	0.49	0.34	0.70	<0.001
Iatrogenic birth for fetal compromise ≥ 37 weeks	1,751	18.11	392	15.16	1.19	1.08	1.32	0.00	1.11	1.00	1.24	0.040
Iatrogenic birth for fetal compromise < 37 weeks	102	1.06	59	2.28	0.46	0.34	0.64	0.00	0.49	0.34	0.70	<0.001

\*adjusted for maternal age, metropolitan vs regional residence, smoking status, need for interpreter, body mass index, region of birth, socioeconomic index for postcodes, diabetes mellitus, parity, infant sex, gestation at first antenatal visit  
aOR, adjusted odds ratio; cLMP, calculated last menstrual period; IPTWRA, inverse proportionality treatment weighted regression adjustment; L, lower limit of 95% confidence interval; SCN, special care nursery; NICU, neonatal intensive care unit; OR, odds ratio; PPH, postpartum hemorrhage; TOP, termination of pregnancy; U, Upper limit of 95% confidence interval



Table 4. Sensitivity analysis for congenital anomalies, stillbirths, preterm births, and nursery admissions among all births

Outcomes	Vaccinated		Unvaccinated		Unadjusted Odds Ratio (IPTWRA)				Adjusted Odds Ratio*(IPTWRA)			
					OR	L	U	P value	aOR	L	U	P value
Singleton cLMP cohort vaccinated < 20 weeks	N=2442		N=2668									
	n	%	n	%								
Congenital anomalies	66	2.6	83	3.0	0.87	0.63	1.20	0.400	0.80	0.57	1.13	0.21
Singleton cLMP cohort vaccinated < 24 weeks excluding congenital anomalies, terminations of pregnancy and births < 24 weeks	N=2442		n=4665									
	n	%	n	%								
Stillbirths												
Stillbirths	6	0.1	21	0.8	0.16	0.06	0.39	<0.001	0.17	0.07	0.44	<0.001
Stillbirths >37 weeks	2	0.0	3	0.1	0.37	0.06	2.23	0.28	0.22	0.04	1.39	0.11
Stillbirths <37 weeks	4	0.1	18	0.7	0.12	0.04	0.37	<0.001	0.15	0.05	0.47	0.001
Preterm birth < 37 weeks												
Total	231	5.0	239	9.2	0.54	0.45	0.64	<0.001	0.58	0.48	0.71	<0.001
Spontaneous	114	2.4	104	4.0	0.61	0.47	0.80	<0.001	0.73	0.73	0.99	0.046
Iatrogenic	117	2.5	135	5.2	0.73	0.54	0.99	0.046	0.48	0.36	0.63	<0.001
Newborn outcomes												
SCN admission	422	9.1	281	10.9	0.84	0.73	0.97	0.016	0.90	0.77	1.05	0.19
NICU admission	134	2.9	106	4.1	0.71	0.55	0.91	0.006	0.81	0.61	1.09	0.17

\*adjusted for maternal age, metropolitan vs regional residence, smoking status, need for interpreter, body mass index, region of birth, socioeconomic index for postcodes, diabetes mellitus, parity, infant sex, gestation at first antenatal visit  
aOR, adjusted odds ratio; cLMP, calculated last menstrual period; IPTWRA, inverse proportionality treatment weighted regression adjustment; L, lower limit of 95% confidence interval; SCN, special care nursery; NICU, neonatal intensive care unit; OR, odds ratio; PPH, postpartum hemorrhage; TOP, termination of pregnancy; U, Upper limit of 95% confidence interval

Table 5. Selected outcomes among women with documented COVID-19 infection by vaccination status

Outcomes	Vaccinated		Unvaccinated		Unadjusted Odds			
	N=9927		N=2752		OR	L	U	P value
	count	(%)	count	(%)				
Singleton cLMP cohort with COVID-19 infection	N=355		N=163					
Congenital anomalies	9	2.5	4	2.5	1.0	0.3	3.4	0.96
Singleton cLMP cohort excluding congenital anomalies, TOP, and births < 24 weeks with COVID-19 infection	N=346		N=158					
Stillbirths	1	0.3	2	1.3	0.2	0.0	2.5	0.23
Total preterm birth < 37 weeks	8	2.3	11	7.0	0.3	0.1	0.8	0.02
Spontaneous preterm birth	1	0.3	4	2.5	0.1	0.0	1.0	0.05
Iatrogenic preterm birth	7	2.0	7	4.4	0.5	0.2	1.3	0.14

cLMP, calculated last menstrual period; L, lower limit of 95% confidence interval; OR, odds ratio; TOP, termination of pregnancy; U, Upper limit of 95% confidence interval

## Figure legends.

Figure 1. Total births and calculated last menstrual period (cLMP) cohorts

Figure 2. Flowchart of study cohorts

Figure 3. Weekly percentage of births to vaccinated women July 2021 to March 2022

Figure 4. Weekly rate of births to women with COVID-19 infection during pregnancy

Figure 5. Socioeconomic index for areas and maternal vaccination coverage by postcode

The participating hospitals are indicated by the lettered circles with their corresponding vaccination rates displayed in Figure 6.

Figure 6. Forest plots of vaccination coverage by hospital\*


\*The hospital level data is grouped here by maternity service level. Level 6 maternity services provide regional/statewide specialised care for high risk pregnancies, including extremely preterm births, as well as local care for all women and babies; Level 5 services care for normal to moderate risk pregnancies, and manage labor and birth from 31 weeks gestation; Level 4 services that provide local care for women and babies at normal and moderate risk, including planned births from 34 weeks gestation. The geographical location of each hospital are indicated in Figure 5.


Figure 7. Timing of first and second COVID-19 vaccine doses during pregnancy\*


\*Calculated on the singleton cLMP cohort > 20 weeks gestation


Figure 8. Hazard ratio plots for stillbirth and preterm birth for women vaccinated before 24 weeks gestation\*

\*Plots were generated using the multiple imputed dataset and included adjustment for pertussis vaccination status












### SEIFA Quintile





### Proportion Vaccinated











### Stillbirths



Number at risk					
Unvaccinated	2606	2575	2534	2444	821
Vaccinated	4665	4653	4631	4528	1551

Adjusted HR: 0.17, 95% CI 0.06 - 0.46

### Preterm Births



Number at risk					
Unvaccinated	2601	2575	2545	2506	2367
Vaccinated	4663	4653	4637	4592	4434

Adjusted HR: 0.54, 95% CI 0.44 - 0.67